Cellectis SA (NASDAQ:CLLS) has earned a consensus rating of “Buy” from the six ratings firms that are currently covering the stock. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $46.60.

A number of research firms have recently weighed in on CLLS. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and issued a $65.00 target price on shares of Cellectis SA in a research report on Wednesday, September 14th. Piper Jaffray Cos. set a $41.00 target price on shares of Cellectis SA and gave the stock a “buy” rating in a research report on Thursday, November 24th. Jefferies Group reissued a “buy” rating on shares of Cellectis SA in a research report on Friday, August 5th. Finally, Zacks Investment Research raised shares of Cellectis SA from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a research report on Thursday, October 20th.

Cellectis SA (NASDAQ:CLLS) opened at 17.62 on Friday. The stock has a 50 day moving average of $0.00 and a 200 day moving average of $0.00. The stock’s market cap is $622.57 million. Cellectis SA has a 1-year low of $16.35 and a 1-year high of $34.99.

A number of institutional investors have recently bought and sold shares of CLLS. Perceptive Advisors LLC boosted its position in shares of Cellectis SA by 6,025.1% in the second quarter. Perceptive Advisors LLC now owns 183,507 shares of the company’s stock valued at $4,879,000 after buying an additional 180,511 shares during the period. Taube Hodson Stonex Partners LLP boosted its position in shares of Cellectis SA by 58.6% in the second quarter. Taube Hodson Stonex Partners LLP now owns 269,776 shares of the company’s stock valued at $7,173,000 after buying an additional 99,664 shares during the period. Morgan Stanley boosted its position in shares of Cellectis SA by 1,034.6% in the third quarter. Morgan Stanley now owns 64,817 shares of the company’s stock valued at $1,561,000 after buying an additional 59,104 shares during the period. Baker BROS. Advisors LP acquired a new position in shares of Cellectis SA during the third quarter valued at $1,204,000. Finally, GAM Holding AG boosted its position in shares of Cellectis SA by 258.5% in the third quarter. GAM Holding AG now owns 54,570 shares of the company’s stock valued at $1,314,000 after buying an additional 39,350 shares during the period. Institutional investors and hedge funds own 19.79% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Brokerages Set Cellectis SA (CLLS) PT at $48.00” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be read at https://www.thecerbatgem.com/2016/11/30/brokerages-set-cellectis-sa-clls-pt-at-48-00.html.

Cellectis SA Company Profile

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

5 Day Chart for NASDAQ:CLLS

Receive News & Stock Ratings for Cellectis SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis SA and related stocks with our FREE daily email newsletter.